Sanofi ADR

SNY

NASDAQ. Currency in USD

46.98 0.00 ( 0.00% )

Real time prices: December 19

Market Cap.
119.09B
Beta (5Y monthly)
0.42
Price/Earnings
1.07
EPS (TTM)
43.98
Forward Dividend
1.75 (3.65%)
Ex-Dividend Date
May 27, 2022
Volume
2.13M
1y Target Est.
63.10
Day's Range
46.82
-
47.28
52 Week's Range
36.91
-
58.10

Historical Summary

Performance
EPS growth
Share Buybacks

About Sanofi ADR

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.sanofi.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
2.50B
Employees
95442
Address
54, Rue La BoEtie, Paris, France, 75008
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Latest news

5 Momentum Stock Bargains Hunters Would Love Chasing
5 Momentum Stock Bargains Hunters Would Love Chasing

Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK,...
By Zacks Investment Research - 6 weeks ago

These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners

Business wins are shining the spotlight on these two companies.
By The Motley Fool - 6 weeks ago

What Makes Sanofi (SNY) a New Buy Stock
What Makes Sanofi (SNY) a New Buy Stock

Sanofi (SNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about...
By Zacks Investment Research - 6 weeks ago

SNY vs. LLY: Which Stock Is the Better Value Option?
SNY vs. LLY: Which Stock Is the Better Value Option?

SNY vs. LLY: Which Stock Is the Better Value Option?
By Zacks Investment Research - 6 weeks ago

Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion
Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion

Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of...
By Zacks Investment Research - 6 weeks ago

Amgen reportedly in talks to buy Horizon Therapeutics
Amgen reportedly in talks to buy Horizon Therapeutics

The U.S. biotechnology company AMGN was the last of three suitors standing in an auction...
By MarketWatch - 6 weeks ago

Will This Potential Approval Be a Winner for Sanofi's Shareholders?
Will This Potential Approval Be a Winner for Sanofi's Shareholders?

Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in...
By The Motley Fool - 7 weeks ago